Join today and have your say! It’s FREE!

We will not release or resell your information to third parties without your permission.

Please Try Again

{{ error }}

By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Please Try Again

{{ error }}

Password Hint : {{passwordHint}}

Remember me

Forgot Password?

or

Privacy Policy | Disclaimer

Quote | Bullboard | News | Opinion | Profile | Peers | Filings | Financials | Options | Price History | Ratios | Ownership | Insiders | Valuation

Breaking & Recent News BG Medicine Inc BGMD

Metals & Mining Technology Industrial Metals & Minerals Scientific & Technical Instruments

BG Medicine, Inc. (BG Medicine) is a commercial-stage diagnostics company. The Company is engaged in commercializing diagnostic products that may be used to help guide the care and management of patients suffering from heart failure and related disorders. The Company's BGM Galectin-3 Test is an in vitro diagnostic device that employs a manual micro-titer platform to measure galectin-3 levels in... see more

Add To Watchlist

Recent & Breaking News (GREY:BGMD)

Trenton Health Team Adopts Novel Diagnostic Tool, BGM Galectin-3(R) Test, to Reduce Hospital Readmissions

Globe Newswire May 8, 2013

BG Medicine to Announce First Quarter 2013 Financial Results and Host Conference Call on Thursday, May 9, 2013

Globe Newswire May 2, 2013

BG Medicine Welcomes CE Mark for Galectin-3 Test

Globe Newswire April 10, 2013

Abbott's Galectin-3 Test Provides Doctors in Europe with New Tool for Assessing the Prognosis of Chronic Heart Failure Patients

PR Newswire April 10, 2013

Free Research Reports on BGMD, BIOF, GEVO and MLNX Issued by the Bedford Report

Marketwired April 8, 2013

BG Medicine Reports Fourth Quarter and Full Year 2012 Financial Results and Provides 2013 Outlook

Troy Schwensen March 13, 2013

BG Medicine Highlights Role of Galectin-3 Testing in Combating Hospital Readmissions at the American College of Cardiology's (ACC) 62nd Annual Scientific Session & Expo

Troy Schwensen March 6, 2013

BG Medicine to Announce Fourth Quarter and Year-End 2012 Financial Results and Host Conference Call on Wednesday, March 13, 2013

Troy Schwensen March 6, 2013

BG Medicine, Inc. to Present at Cowen and Company 33rd Annual Health Care Conference

Troy Schwensen February 27, 2013

BG Medicine, Inc. Announces Publication of Two Studies Supporting Repeat Galectin-3 Testing in Heart Failure Patients

Troy Schwensen February 27, 2013

Free Research Report on Brunswick Corp., BG Medicine, Inc., BioScrip, Inc., Bloomin' Brands, Inc. and Blount International, Inc.

PR Newswire January 31, 2013

BG Medicine, Inc. Announces Closing of Public Offering and Exercise of Over-Allotment Option

Troy Schwensen January 30, 2013

Free Research Reports on BGMD, MCP, RSH and THLD Issued by the Bedford Report

Marketwired January 28, 2013

BG Medicine, Inc. Prices $12.0 Million Public Offering of Common Stock

Troy Schwensen January 25, 2013

BG Medicine, Inc. Enters Into $12 Million Common Stock Purchase Agreement With Aspire Capital Fund, LLC

Troy Schwensen January 24, 2013

BG Medicine, Inc. Announces Proposed Public Offering of Common Stock

Troy Schwensen January 24, 2013

Biotech Industry Expected to Experience More M&A Activity in 2013

Marketwired January 21, 2013

The Real Story Behind ZAGG, CLSN, YELP and BGMD

Marketwired January 8, 2013

Free Research Reports on BGMD, FOLD, PPHM and TSL Issued by the Bedford Report

Marketwired January 4, 2013

BG Medicine Announces Obtaining CE Mark and Launching of Automated BGM Galectin-3 Test

Troy Schwensen January 2, 2013